Alexander Benedikt Leichtle

Prof. Dr. Alexander Benedikt Leichtle

University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2005 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
SBSven Baumann
Sven Baumann
UCUta Ceglarek
Uta Ceglarek
GFGeorg Martin Fiedler
Georg Martin Fiedler
JLJan Lembcke
Jan Lembcke
ALAlexander Benedikt Leichtle
Alexander Benedikt Leichtle
JTJoachim Thiery
Joachim Thiery
Background: Magnetic bead purification for the analysis of low-abundance proteins in body fluids facilitates the identification of potential new biomarkers by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). The aims of our study were to establish a proteome fractionation technique and to validate a standardized blood sampling, processing, and storage procedure for proteomic pattern analysis. Methods: We used magnetic bead separation for proteome profiling of human blood by MALDI-TOF MS (mass range, 1000–10 000 Da) and studied the effects on the quality and reproducibility of the proteome analysis of anticoagulants, blood clotting, time and temperature of sample storage, and the number of freeze–thaw cycles of samples. Results: The proteome pattern of human serum was characterized by ∼350 signals in the mass range of 1000–10 000 Da. The proteome profile showed time-dependent dynamic changes before and after centrifugation of the blood samples. Serum mass patterns differed between native samples and samples frozen once. The best reproducibility of proteomic patterns was with a single thawing of frozen serum samples. Conclusion: Application of the standardized preanalytical blood sampling and storage procedure in combination with magnetic bead-based fractionation decreases variability of proteome patterns in human serum assessed by MALDI-TOF MS.

1 August 2005 in Clinical Chemistry
Verified
Journal Article
Closed access
PDF file
JKJuergen Kratzsch
Juergen Kratzsch
GFGeorg Martin Fiedler
Georg Martin Fiedler
ALAlexander Benedikt Leichtle
Alexander Benedikt Leichtle
MBMatthias Brügel
Matthias Brügel
SBSusanne Buchbinder
Susanne Buchbinder
JTJoachim Thiery
Joachim Thiery
Background: The aim of our present study was to establish new reference intervals for thyrotropin (TSH) and thyroid hormones based on National Academy of Clinical Biochemistry (NACB) criteria and regular thyroid ultrasonography. We also assessed the effect of potentially confounding factors to modulate the limits of these intervals. Methods: We investigated 870 apparently healthy persons and excluded, step by step, those with a family history of thyroid disease, pathologic thyroid ultrasonography results, and increased anti-thyroid peroxidase or anti-thyroglobulin antibodies. Accordingly, only 453 of the 870 persons in the entire group were finally included as reference collective. We measured serum concentrations of TSH, total and free thyroxine (T4 and FT4), and total and free triiodothyronine (T3 and FT3) of the whole and the reference collective on the ELECSYS system assays (Roche Diagnostics) and calculated the 2.5th and 97.5th percentiles for comparison. Results: The calculated lower limit for TSH differed significantly between the reference intervals for healthy persons with an assessed normal thyroid gland vs the nonselected group of healthy blood donors. Age was the only independent factor and was significantly inversely associated with TSH (P <0.0001). Use of oral contracep-tives was a significant predictor for variation in T4 concentrations (P <0.001). Age and oral contraceptives were independently associated with T3 variations (P <0.05). For FT4 vs FT3 variation, gender and (inversely) age (P <0.01) were independent modulating factors. Conclusions: The selection of healthy persons according to NACB criteria combined with sonographic confirmation of a normal thyroid gland provide a valid basis for the reference interval for TSH. Factors indicating a preclinical disease state, such as family history, pathologic ultrasonography result, or increased anti-thyroid peroxidase and anti-thyroglobulin antibodies, can be associated with normal hormone concentrations. Additionally, patient age and gender as well as use of contraceptives should be considered in diagnostic evaluation of thyroid diseases.

1 August 2010 in Circulation: Cardiovascular Genetics
Verified
Journal Article
Closed access
DTDaniel Teupser
Daniel Teupser
RBRonny Baber
Ronny Baber
UCUta Ceglarek
Uta Ceglarek
MSMarkus Scholz
Markus Scholz
TIThomas Illig
Thomas Illig
JTJoachim Thiery
Joachim Thiery
Background—: Phytosterols are plant-derived sterols that are taken up from food and can serve as biomarkers of cholesterol uptake. Serum levels are under tight genetic control. We used a genomic approach to study the molecular regulation of serum phytosterol levels and potential links to coronary artery disease (CAD). Methods and Results—: A genome-wide association study for serum phytosterols (campesterol, sitosterol, brassicasterol) was conducted in a population-based sample from KORA (Cooperative Research in the Region of Augsburg) (n=1495) with subsequent replication in 2 additional samples (n=1157 and n=1760). Replicated single-nucleotide polymorphisms (SNPs) were tested for association with premature CAD in a metaanalysis of 11 different samples comprising 13 764 CAD cases and 13 630 healthy controls. Genetic variants in the ATP-binding hemitransporter ABCG8 and at the blood group ABO locus were significantly associated with serum phytosterols. Effects in ABCG8 were independently related to SNPs rs4245791 and rs41360247 (combined P =1.6×10 −50 and 6.2×10 −25 , respectively; n=4412). Serum campesterol was elevated 12% for each rs4245791 T-allele. The same allele was associated with 40% decreased hepatic ABCG8 mRNA expression ( P =0.009). Effects at the ABO locus were related to SNP rs657152 (combined P =9.4×10 −13 ). Alleles of ABCG8 and ABO associated with elevated phytosterol levels displayed significant associations with increased CAD risk (rs4245791 odds ratio, 1.10; 95% CI, 1.06 to 1.14; P =2.2×10 −6 ; rs657152 odds ratio, 1.13; 95% CI, 1.07 to 1.19; P =9.4×10 −6 ), whereas alleles at ABCG8 associated with reduced phytosterol levels were associated with reduced CAD risk (rs41360247 odds ratio, 0.84; 95% CI, 0.78 to 0.91; P =1.3×10 −5 ). Conclusion—: Common variants in ABCG8 and ABO are strongly associated with serum phytosterol levels and show concordant and previously unknown associations with CAD.

1 March 2007 in Clinical Chemistry
Verified
Journal Article
Closed access
PDF file
GFGeorg Martin Fiedler
Georg Martin Fiedler
SBSven Baumann
Sven Baumann
ALAlexander Benedikt Leichtle
Alexander Benedikt Leichtle
AOAnke Oltmann
Anke Oltmann
JKJulia Kase
Julia Kase
UCUta Ceglarek
Uta Ceglarek
Background: Peptidome profiling of human urine is a promising tool to identify novel disease-associated biomarkers; however, a wide range of preanalytical variables influence the results of peptidome analysis. Our aim was to develop a standardized protocol for reproducible urine peptidome profiling by means of magnetic bead (MB) separation followed by matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS).

1 January 2005 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
JLJan Lembcke
Jan Lembcke
UCUta Ceglarek
Uta Ceglarek
GFGeorg Martin Fiedler
Georg Martin Fiedler
SBSven Baumann
Sven Baumann
ALAlexander Benedikt Leichtle
Alexander Benedikt Leichtle
JTJoachim Thiery
Joachim Thiery
A novel analytical platform based on liquid chromatography and tandem mass spectrometry using atmospheric pressure photoionization was applied for the simultaneous quantification of free and esterified β-sitosterol, campesterol, brassicasterol, and stigmasterol. The total time for sample pretreatment and analysis could be reduced from ∼3 h [gas chromatography-mass spectrometry (GC-MS)] to 15 min. The detection limits of the different phytosterols ranged between 0.25 and 0.68 μg/l. Linear ranges were between 1 and 1,000 μg/l. The within-run and between-run variabilities ranged between 1.4% and 9.9%. The analytical sensitivity was at least 150-fold higher compared with GC-MS.

16 September 2011 in Metabolomics
Verified
Journal Article
Open access
PDF file
ALAlexander Benedikt Leichtle
Alexander Benedikt Leichtle
JNJean-Marc Nuoffer
Jean-Marc Nuoffer
UCUta Ceglarek
Uta Ceglarek
JKJulia Kase
Julia Kase
TCTim OF Conrad
Tim OF Conrad
GFGeorg Martin Fiedler
Georg Martin Fiedler
Mass spectrometry-based serum metabolic profiling is a promising tool to analyse complex cancer associated metabolic alterations, which may broaden our pathophysiological understanding of the disease and may function as a source of new cancer-associated biomarkers. Highly standardized serum samples of patients suffering from colon cancer (n = 59) and controls (n = 58) were collected at the University Hospital Leipzig. We based our investigations on amino acid screening profiles using electrospray tandem-mass spectrometry. Metabolic profiles were evaluated using the Analyst 1.4.2 software. General, comparative and equivalence statistics were performed by R 2.12.2. 11 out of 26 serum amino acid concentrations were significantly different between colorectal cancer patients and healthy controls. We found a model including CEA, glycine, and tyrosine as best discriminating and superior to CEA alone with an AUROC of 0.878 (95% CI 0.815–0.941). Our serum metabolic profiling in colon cancer revealed multiple significant disease-associated alterations in the amino acid profile with promising diagnostic power. Further large-scale studies are necessary to elucidate the potential of our model also to discriminate between cancer and potential differential diagnoses. In conclusion, serum glycine and tyrosine in combination with CEA are superior to CEA for the discrimination between colorectal cancer patients and controls.